Sunitinib (SU) pharmacokinetic (PK)–pharmacodynamic (PD) modeling with respect to safety and efficacy endpoints in Asian patients (pts) with gastrointestinal stromal tumor (GIST) or renal cell carcinoma (RCC) in pursuit of a therapeutic window.

R. Khosravan,G. Mugundu,N. Agata,E Ueda,T. Nishida,H Akaza

Sunitinib (SU) pharmacokinetic (PK)–pharmacodynamic (PD) modeling with respect to safety and efficacy endpoints in Asian patients (pts) with gastrointestinal stromal tumor (GIST) or renal cell carcinoma (RCC) in pursuit of a therapeutic window.

2011

R. Khosravan
G. Mugundu
N. Agata
E Ueda
T. Nishida
H Akaza

e15128 Background: SU is an oral multitargeted tyrosine kinase inhibitor, approved multinationally for the treatment of advanced RCC, imatinib-resistant or -intolerant GIST, and well-differentiated...

Keywords:

Pathology
Pharmacodynamics
Stromal tumor
Renal cell carcinoma
Therapeutic window
Medicine
Sunitinib
Pharmacokinetics
Tyrosine-kinase inhibitor
Internal medicine
GiST
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations